Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million

Palvella Therapeutics shared on LinkedIn:

“Today, we announced Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million which will support the advancement of our ongoing Phase 3 single-arm baseline-controlled trial in microcystic lymphatic malformations.

This underscores our belief in the potential of QTORIN™ rapamycin which has also received FDA Breakthrough Therapy, Fast Track, and Orphan Designations for this serious, rare and chronically debilitating genetic disease.

Learn more here.”

Source: Palvella Therapeutics/LinkedIn